<SEC-DOCUMENT>0001144204-14-027063.txt : 20140502
<SEC-HEADER>0001144204-14-027063.hdr.sgml : 20140502
<ACCEPTANCE-DATETIME>20140502122357
ACCESSION NUMBER:		0001144204-14-027063
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140502
FILED AS OF DATE:		20140502
DATE AS OF CHANGE:		20140502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		14808074

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v377078_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of May, 2014 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number </B>_________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Novogen Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>16-20 Edgeworth David Ave, Hornsby, NSW
2077, Australia </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Novogen Limited </B>(Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Lionel Mateo </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lionel Mateo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date 2 May 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v377078_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">
<p style="text-align:center"><b>Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases</b></p></div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>SYDNEY, May 2, 2014 /PRNewswire/ -- Novogen Limited (NASDAQ: NVGN, ASX: NRT;), an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.</p><div style="TEXT-ALIGN: left; WIDTH: 100%"><img src="ny36990logo.jpg" id="prni2b2eleft" title="Novogen Logo." border="0" alt="Novogen Logo." align="middle"></div><p>Preliminary research conducted by both companies found that super-benzopyrans appear to be effective at promoting the &#39;normalization&#39; of stem cells associated with some forms
of neurodegeneration and muscular dystrophy, genetic disorders which result in progressive deterioration of brain function or muscle strength and function.</p><p>&#34;SBPs have already been shown to be highly effective at killing cancer stem cells, which were previously considered resistant to anti-cancer therapy.  But in some of our studies, we found in certain instances, some of these drugs actually appeared to normalise both the behaviour and appearance of the cancer cells. It was that observation that set us on the path to testing their ability to do the same thing with stem cells carrying genetic disorders,&#34; said Dr. Graham Kelly, CEO of Novogen.</p><p>Genea Biocells is a world leader in the field of embryonic stem cells with genetic disorders. The cells have been sourced from embryos donated by couples undergoing in vitro fertilisation and pre-implantation genetic diagnosis
(PGD). PGD enables the genetic testing of embryos before they are implanted to make sure babies born are not affected by a genetic disease. Genea is using those stem cell lines to test compounds to identify potential clinical development candidates. </p><p>&#34;Super-benzopyrans are the first drug class we have seen with the ability to selectively modulate misbehaving stem cells,&#34; said Dr. Uli Schmidt, General Manager of Genea Biocells.</p><p>&#34;Effected embryos identified during the PGD process cannot be used for implantation but can instead be donated by patients to develop stem cell lines carrying the genetic disease. These disease-specific cell lines can now be used to test the effectiveness of exciting new compounds that are thought to counteract the disease. The testing of new molecules on individual stem cells holds great promise in the pursuit of new therapies,&#34; Dr.
Schmidt said. &#34;The collaboration with Novogen opens up an entirely new opportunity for the development of therapies for some of the most debilitating and life-threatening diseases and disorders in children and adults.&#34;</p><p>Novogen will partner with Genea Biocells to test the molecules in laboratory models across a range of degenerative diseases including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, amyotrophic lateral sclerosis (motor neurone disease), Sanfillipo syndrome and Alzheimer&#39;s Disease.</p><p>The collaboration is on the basis of pooling respective resources, with each company retaining its own intellectual property rights and commercial opportunities.</p><p><b>About Novogen
<br /></b>Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange (&#39;NRT&#39;) and NASDAQ (&#39;NVGN&#39;).  The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing an intra-peritoneal product for cancers such as ovarian cancer that are limited to the abdomen.</p><p>Further information is available on the
Company&#39;s website, www.novogen.com.  </p><p><b>About Genea Biocells
<br /></b>Genea Biocells Pty Ltd develops unique human stem cell tools to advance research and drug discovery in areas of unmet medical need. Genea Biocells offeres specialized contract research services and custom-developed, cell-based assay solutions in drug development. It also supplies application-ready, disease-affected and control differentiated cell types as well as culture media and pluripotent stem cell lines.</p><p><b>Contact</b></p><p><b>In the USA
<br /></b>Lazar Partners
<br />David Carey (investors)
<br />Hollister Hovey/Allison Parks (media)
<br />+1 212-867-1762
<br />Novogen@lazarpartners.com </p><p><b>In Australia and ROW
<br /></b>Instinctif Partners
<br />Dr. Douglas Pretsell (Australia)
<br />+61 (0)3 9657 0706</p><p>Sue Charles/Stefanie Bacher (ROW)
<br />+44 (0)20 7457 2020
<br />Novogen@instinctif.com </p><p>Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO</p>
<br /><br /><p>
</p><p> </p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ny36990logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ny36990logo.jpg
M_]C_X``02D9)1@`!`@```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`0$"`0$!`@("`@("`@("`0("`@("`@("`@+_
MVP!#`0$!`0$!`0$!`0$"`0$!`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@+_P``1"`"3`9`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBD)P,
MX)^E&XFTE=Z)"T5`TVUU7RY&W#.X`$9YXQG/0'GI[U*'![$>QP"/KD]:7,K7
MOHBK/3^]JAU%,,@`SC]0/Z\4TS+M+*"X']WGCN1Z_A36JNMD)Z)MIV7DR6BH
MHI5E!*@C:VT@C!R*EH#U37JK/[GJ%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%(Q`'/.?\"?Z4M13,JKEFV@Y&<XQE6&3[#.?PI./
M-IW$W97>B1YE\7OBCX3^#'PW\=?%/QWJ=OI'@WX?^%M4\5^(M0FR1;Z;I=I=
M7D@CC4YGG=K<Q11KEI99EC523@_Q:>(_^#D3]M*X\0:Y-X7\#_!?3/#3ZOJ)
MT#3M7\+:SJ.JV&D?:YA86FJ7]OXHBCO-1CMA&D\D<<<;RJS)&BD*/LW_`(.,
MOVWY;72_"7[$7@#66AGU<Z9XY^-M[9SR+):::'2?P3X,FEA8#SIKWRM4N8CP
M8;&UR2DCJW\CJLS@.V4=\M*BLVU)F.Z:-3GE%E+@>RC/-?E'&/%F.P^/67Y9
MBOJ\*.LI0UDWHK-[:?F?Z0_19^CKPOFW!.)XN\0<@AFU7/JD98"AB5-*&"LW
M#$12<'^^G&2A9M>SBFTFU?\`?S_B(^_;P_Z%7X##/?\`X0K7Q@GW_P"$OXYK
M8T'_`(.2?VV;36](O/$?@7X)ZSX>M=1LIM=TO3/"^M6&JZAI*7$9O['2[V?Q
M4ZVNHRV_F)!*R.D4CK)(CHC(W\]O/]YO^^F_QIC[PKE6.[:Q&YB5!"G`()[G
M`XZEJ^0CQ5Q`I4YO-:CE%ZJRM;3SWW/Z=J?1S\$9TZD7X=9?-UHS@^:-6T.:
M-HU(6K*\XRUL[*R6NY_JP_!7XK>#?CC\+?!'Q=^'VK1:WX,^(7A[3?%'A^_B
MW!FLM3MUF-M<QN=T%]!.9H+B)L-%-;R1D`K7J5?R3?\`!N?^V^AC\5?L1^.M
M8<W4#:KX\^"M[>S2#[396QA;QOX-*32?+<0RO%?V@7Y3&U^2"5%?UF(6VE?-
M;."RLQ))0XVDG'4`<^YK]QR',HYQEM#%J5ZCBN=.R:DM]%=6[>35]3_(GQ9\
M/<;X7\=YWPCBN:I0P<E5PU9Q<57PE5WIU(\S;:A=PGKI*,K75F7:*0=!WX'/
MK2UZQ^<!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%>"?M/
M_'3PS^S1\!OB=\=_%UK>7^A?#/PKJ/B2XT[3U9KS5;JWC$6F:3`RJ1"]UJDU
MG!YKCRH1.992(U8U[W7"?$WP#X2^*?@/Q5\.?'>D6>O^#_&NA:GX;\1Z-?KO
MMM1TG5K.6SO;8@$%)3!*YC=2&CD574@J#45%.5.I&F^6HXM1>^MG;\3ORN>`
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MBEHY5@$L3O&RL?\`-M_8W_9D\4?M?_M(_"_X!^%UG@;QIKF_Q#K4(/\`Q37@
MK14CU/QGKID\MEC\G1(Y&0,`TMS':11!MTA3_06^/?QS^$?_``3E_9J\(-8^
M&#-X=\*V_A[X=?#CX?:1=VNF:AK#VED-\-M<R1LJ&+2K&>[NYO+=<MDYDE56
M_7_"[!9GB:N+H4:<JM'$65)6O>K>SBO*VK^]L_S,_:%<3\#9%A>%L5F]>.`X
M@RC#8K%8NNW"U/*+J%/VUES-SKJ7U>%^91IU='SQ/OGSH1QYB<<?>';\:/.A
M_P">J?\`?0_QK^>C_A_KX(_Z-K\7=_\`FH&B?_*3BD/_``7T\%$87]FWQ<IS
MU_X6!HAY'TT48%?NO^HO%=[?V1-7[N%NG]X_R7C])+P6T2XXPKO9))5KZVM:
M])+\?F?T,>?%D#S%)/H0?Y5*#D9'^'\Z_(G]C[_@J_\`#S]JSXKQ?"B?X?ZU
M\--<U+2K^_\`#MSK7B#3]9L]>N]-59[W28&M;6(Q7HL#-,H(*LMNR[@[(K?K
ME$VZ-6]<Y]CDY'MSV[5X69Y7F&3XI8/,,)+#5>7F]ZW5VLK?/576A^G<+<7\
M/<:9=/-.&\PCF.#I3]G*<>D[7M9ZK374DHHHK@/I0HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`J*50RC)VD,"K#&5;!P1N4\_A4M,D^[DYP""<#)X]!WY
MQ4RNE=;IK\T#O]G5]#^<W_@X,_8=_P"%V?`;3_VFO`VC/<_$GX`V\S^*_L$8
M-[X@^$TSM_:T4H1,R7FDW%PVH0R$E([9;T212[H3!_$%R22IC8,S-O161'+$
MLTB(68QHS$L%+,RAMI8D$U_K&:WHFEZ]I>K:'K-I%J.DZW97NDZMIUW`MQ::
MCI^J6LUG=6$\$@*RP26\\JNI!5E;!%?S5^(O^#97]G_6?$&MZMHW[1OQ8\,Z
M5J>JW]_IWAVT\)>$]0M-#M+NYDGATJTO;V02W%K`CB.,R#<$0*2<9K\XXOX3
MQ>/QWUS*J$93KV=57M>25N=WZVTTZ>;/[R^C1])GAK@7A#$<%>(&95<+E^45
MI2RRO&C6KSG"L[XBC+V-.I)1I54G!R25I<J=D?QC_-WQ^'<]AS43/(`2`HPK
M_,P8JIVD)D`_,/-*?*,%_N`JS!A_9*?^#8/X(\X_:G^+^><?\4/X*(_2;I6I
MX=_X-EOV?](\1Z%J?B#]H_XL>(=#TW6-.U#5O#ESX5\(Z=!K^GV5W'<W>CW%
M_;2>;8P7$,3QR2QYDC61F3!`-?*TN!,^J2@JU"-*/-JTU>VE^NWIJ?T?6^F)
MX(4J=2K3XCQ,JF&C.<(_V=BI*M4<;0I2=2E3:CS6>R6OQ=%W'_!OE^Q/!\'_
M`(#ZO^U/XUTI8O'?Q[M4A\)2WBJTNC?"#3[PW&G+:^9"OD-K%];_`&Z>0_Z^
MVM+(!412K_G]_P`%1_VJI/VD_P!HS5=$T/4Y+SX:_![[=X-\'6\<N8-2UF+S
M(_&WB145SYCW&IV-E:K)D'R=*01[0[F3]YO^"E_[2>D_LD_LM#P)X%73]#\7
M_$'1W^&OPZT33W6T7P]X=L=/M=/\1:K9+"J"TM;'1;B&RMY@NV*[U>R(&.G\
M=A+*Q.Z5W5BKRSJ4N&D23>YG#$LLYF!9PQ)WYSWK^Q/![A.&4X&EF%:DH4\/
M^ZI3Z^W=FZB\[Z:^?2Q_SA_3^\?\U\0^,<9E,Z\X8K.JT<5CH+W50I4$HY?@
M^1W4:<Z#G5E!/E<H\SU;&$C)X!YZY//OUHSZ`#OD9SQ^-)17[Q=]9-_,_P`X
M7:WO:I=]5TMIMHTGMT.L\"^-?$?PX\8^%_B!X1NI++Q+X,U[3/$>BWD1S+#J
M&EW27T&4)_>PLUJ%DC/R2H624.IVU_>#^S-\>]$_:,^"G@#XL^&Y;3[/XHTV
M-M4M(PP.FZW:N;/6]-:(SL89(]2AN`@9V;RY8F8N2<_P)#@Y!((*MP<<KN"G
MZC>WYU^V?_!&']JA_AK\6K_]GKQ5JBCP9\6[N.^\)17,H5-#^(5A!##!%;*7
M^6WU738KN!QCYKNUL\`$N6_//$3(O[4RQYC2AS8O`OFE._O.E:THZZ:.TEI?
M2R/Z5^B[XDRX0XPI\,9M4>&R+BN?(ZE_=AB])4))6T=64?J[LDK5+M72/ZP`
MS;L<$<#([]<U+4$94L,,#G)QGMDC/XDU/7\]/TL?ZAQT5F[M;^3ZKY;!11D>
MHHI#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*:_*D'CW'4<]:=4,\GE(&Y^\`
M.G4G"CD]2Q4#W(S0WRZ]A2U5K<R>EN]]#"U?5=/T>POM7U6ZAL-,TNWN[_4K
MZZF6"ULK+3X&O+J^NIY&"PVT=O$[2.3M5%)8@<U_'W^T9_P5,_:7\6?&KX@:
MQ\'OBUXB\$?#5M7>P\&:!I,-C':1:1I*3VD&I327MM(YO;V\"W,@*#;$51@'
M!4?K3_P68_:R;X6_"&U^`OA34O(\=?&&.9/$20S^7/I?PTBE:+51,B9*G4Y(
MIK+;@;[;[5N9?W8?^4=@49H_N^63$`&+#;$3$I#D`R91%.X@%LY8`DU^R^'7
M"^&K8*MFV8X*.(C6_=PA/5:-2<T^^C2\DNY_`7TI?%S-,-G^`X'X8SC$996R
M->VQV(PM6K2E5JU(VHT7*C*,FJ-.4G.+=N=KJE;[D_X>4?MPG.?VB/&Y'IG2
M.1[_`/$OJ-_^"D?[;C$;OVAO&Z<'F,Z-YIRI&$+:/)\V2,<IROW^Q^'LGOS[
M')%`(!.1V.WV;UP?:OTE</Y&N:V2T+S7+MLN^W_!T/Y1_P"(@\>SC/GXPS&H
MZ?+*//CL9=R33Y5^\>FG^1^Z/Q6:Z_X*)_L`V'QL$ZZS^TG^R9-<Z5\1!#''
M:W_B7P;+:O<7NJ_Z*BLT,]G&-3BD5<QOIFI(B>:VQOPP."[K&`(P9C$JQ"W5
M887*JBP#B+9&%&P<H1M(!!`^Z?\`@GE^TY_PS+^T-X?U/7[B,_##XC(WP\^*
M%C=@2Z?)X=UR6&SL]5NK:0&.?[#J]W92G>,BWDN8ERD\P6I_P4#_`&:6_9D_
M:+\1^']'MV7X=>-$?Q_\+;])/.L9/"^MZC*LMC;7F2LAL+YS;N&)D:(PW)W)
M(7KR\G<\IS.MP[*U/"UI.OE[O[L)Z<U%.VZ;OKI:7D?:\<SI\<<)Y/XAX93K
M9SA:U'+,[BY2J3^L48\^"S"I.=Y1H8FAS8:O.;7[^%*_<^'NM%%%?6MI)MSC
M)K=1DI/SM&+<G\DV?CK<4KN48KSE%)?.XA(498[1ACN/"X39N^8\`_.O'4YX
MK]3?^"6OP&T?QG\6==_:"^(XBT_X-_LS6*>.?$VLWBN=/F\2VEE<ZCH5DR*C
M"^FM8[6>]E6,.ZK:VB$"22-&_,?1='UCQ'JNG>'O#VGRZOKNMZE8:3H^DP1^
M=-J&JZI)+8:7:Q1G@O)J,]JN3PH^9R$4FOVO_;?US1_V,/V3OAE^P3X$OXY?
M'WB^SM_'GQ\UBQ<F26XO9H98[6Z:(*;@:A?PI`B.H46&A*S%=P0_,<3XFI/#
MX?)L)+V>/SEQC";NG2I73J56K72<?W:V=YH_4/#'+\'1K9KQ]FE.-?(^!J;Q
M$97O3K9DG%8+#J<6TU[5JI6BKOV-.I;70\*^)/\`P5S_`&NO$/Q!\8:_\/O'
M[^!_!-_K-[)X.\+CPYX0U"XT?03=O!IMK?WM[X>D>XF.FQQ33_,W^E3N%8J,
MUQ?_``]>_;O_`.BX2?\`A&^!_P#YF*_.;'7UY[>X[]N?Y4E=5/A7ARFN2GE5
M*I&"BOWB3=U&*DT]=').7S/-Q7BWXDXW%XK%T^-LUHK%3=64(XF5%1G4M.:Y
M(W5KOW>O)96/T8_X>O\`[=R2+)_PN@3O&T4BI/X1\&B&4Q%W6WE6'PTK);N0
M!(RG=AUVCBOZL?V/_P!HG2_VG?@)X$^*FE36PO=0L'TKQ;IZS1/+I/BW1]MK
MJUI<1Q(GV;=,HGC78F8+V)E!5E)_@WST]O\`/I]/RK]?O^"/G[4LGP8^.TGP
MA\0ZH\'P_P#C7<6^FVL,\H6STOXD1VIBT/5(XV4A);VWC33IN0)#':M)_J%S
M\AQOPE@:N43QF4X"CA,5@6](I^^K:Z+U37FC]K\`?&_/\LX^P65\8<08G-\H
MXGBL%%8NHZBH8E/F5=U'>Z?PO;?R/Z]I%+1N@8H74H&7!*EAM#`'N"<_A7\J
M?_!43_@HS^VO^S]^VOXW^#7P'\>II7A#1?!O@[Q%9>&X/!'ACQ!?K]K\&67B
M+Q!)#<:G8RRS%8(KV38@+`'<K80@_P!4RW"N0N""<'.1CY6VL.#R0P((]J_D
MK_:X6.?_`(.`?A-;S11S6]YXB^"=C=0SQ)<6\]G?_#F&RO+:ZM95*75M-:SR
MQ/&_R.LQ5N.:_`E)/FL[N+L_)]OQ/],(^\KI65KZIK3RO:_R/V3_`."3?[;6
MH?MF?LWQZKX[U6PU#XR?#K6)_"?Q+DLX;&QCU&5E:\\.^)K?3[*&-+;3[_2Q
M(J%5*M<:1=X.$-?J2"&&1T.?8\'!!'8Y'3J.AK^/7PM<7'_!'O\`X*O7_AV4
M7.B_LQ_&VXBL4@<S/I5I\-/&VHW=]H=U&S*3<R^$/%=K'91R,S21Z>+E6=FO
MR&_L!MYHWMX7C82HT,,BO%*)XWCE4,LT<_'VB(J<AQ]X<]ZH#\#/^"V?[;'[
M1?['C_L^K\`_&UKX+C\<-\1)/$PN?#>BZ_\`V@/#[>%1IH0:E"QM0D=_>_,I
MS\G3[N?V^^%VL:CKOPW^'NNZO/\`:=4USP/X3U?5+E8HHDN-2U30M.O;RX$,
M"!81)=SW#;0-J^PK^9/_`(.5OO?LI?\`7+XO?^B_"=?TG_">[M;#X)?#&_O[
MF&SL;'X6^";R^N[EUCM[:RM?"=E/=SSRN,10K;I*S,2`JJ22*`/`_P!MK]NK
MX,?L-_#A?'7Q-O+C4M=U;[5:^"?A]HQC/BCQAJ5M"9)1;I,P72=$M]\/VO4;
M@""$W,4,?F74\,$GX#Z1^V[_`,%EOV[KR^U3]EWX:_\`"J?AI'=3V4&M:7H>
M@Z3H_$I58I/'OQ$=WUN^5MP;^R_+))_U*]_%_@%X9O\`_@LE_P`%,/&7Q+\?
M_P!HW?[/OPT>7Q)%I,DDL$/_``K[2]433_ACX4`^;[!/KMS;7=WJ20X!CEOF
M9GDBM-O]BOAOPMHGA+1='\->&=*TK0/#>A:9;:3I&AZ/8I8:?IMC9QK%;6]A
M;02".UMTB10%"%AU,A/)`/Y:=?\`AA_P<._#6U?Q5%X^U'QLMBC7+Z+H/B_X
M;>+[AXE4R3(FAZP+#<^0`$22Y9R=JHS8%>@?L?\`_!<GQQIOQ(M/@-^WQX&B
M\!:ZFK6OAU_B3;Z%JGA6^\.:K>M';6L/Q&\%7D'^@6LLY96O[40Q1B59?*DA
M+2I_3PP)!`)'3H<'@Y(SVST]>>*_$_\`X++?L%>$OVAOV?O%?QM\,>';&+XW
M_!S0KKQ)!J]G9QFY\9>"M*AFG\1>%_$4*I_Q-H(M*#W%N\I>5&TT(KJK;:`/
MI?\`X*6?$GXY?##]CGQI\:OV:_&<7ASQ;X!F\->,[N_CTOP_XDTG5_`7]HVE
MEXA6)=7T^XM[BR33M92]2>)5+PZ<9%+#+'&_X)3_`+6GB3]K[]DGPYX]\>:K
M#K7Q1\+^(?$G@3XB7<=G8Z:UUKFDW$.H:9?SZ=IT4<-H\_AZ_P!*<B)!'O\`
M-`/F+(J_$_\`P18^-T7[6O[$/Q+_`&9/B;>/XGN/AKIMY\,YDU1WGFU+X3_$
M30+N+PRM_),&,ODHFL68."T<=HL:9\M:^,_^"''C37/V</VS/VD_V-_&]R]L
M=>EU:*SM[P.DEWX\^$VIZK`]Y"K`>5/>>$[S4I[@*N9&M(."%!4`_K7J.0@!
M00QW21@85FP=P()V@[5R.IP/>I*\L^-WQ1\/_!+X1_$7XN^*64:'\.O".N>*
M[R-G$9NVTJPFGM-/C8CBXN;P6]O%_P!-+E:`/Q`^._[<?[2_C?\`X*J_#G]C
M/]G#QW;>%OA_H=[X;M_BTR>&/#>LS3KI]O!XQ^($_P!LU73KB2VGC\.FUL(4
MB(VW$KD#+;C^N_[3G[5'P?\`V/?A1J'Q4^+^O?V=H-B18Z'HFFQ1WOB;Q3J\
MD?F6.@>&=,,ZB^U%H]O)*1('3?(N]-_X1_\`!!SX7^*?BQ\1_P!IC]O'XG1?
MVAXM\=^)]<\):!JDRQP@ZSXIU6U\8_$34;1&1FM'\N3P[8PJF1!;VT]NNT8#
M?*?QO;7_`/@K7_P5;@^!QUW5X/@)\(=9O_#J6VE7#0VND^!?!$]VWC[Q#IJ-
M&4AU_6=<M(M/2\(\RVBOK01[?(``!ZW_`,/(_P#@JI^WEXCU?3OV(/@S)\._
MAWI]W+8KX@L]*TK5YK>",A/*UOXC>/A;:-_:0PQ>'3X'N4S@PKG(U]1^#7_!
MPYX4M7\31?$J^\02P`S_`/".Z-X^^&&JW<VR-RD26.M6R6ID_P"F(C*DD*K[
ML*W].GPX^&?@GX2>$-`\`_#GPUI'@[P;X9L(M.T;P[HEL;:PLK6%0L:HJN#/
M<8"^9/+YDTY&Z1RW)[QAN&.@/7'!Q['M0!_*=^S[_P`%N?VA?@?\2XO@M_P4
M*^%]_:&&\M]+U;Q=9^%+CPMX[\,33/)''>ZWX620VOBC2C]EN"[V$5M(Z@_9
MTEVA7_J-\(^+?#7C?PSHGB[PCK5AXA\,^(],L]:T+7-+N/M>FZMI>IP1WEE?
M6%TI*W%O)#/&05+!6)C)W*0/SU_X*9?L&^#OVTO@+XEL(="LHOC1X)T+4=>^
M%/BZTM536YM8L;>:[?P9<72-YEQH>J10/:,DAD\BXU"&\@V2P8?\QO\`@WN_
M:?U_7-%^*G[(OCFY:6[^'#2>./AT+MP+W3-`N=5BTGQ=X16`X"Z?8^))8+BV
M"*`K:E=@K%&L*$M?Y`?T)?&?XU?#7X`_#CQ)\5?BMXGLO"O@OPM9"]U#4KO<
M[SR2-LLM.TVV12^H:I<7&V."",%W9LG:BLZ_S'^.O^"RO[<'[6'CW4_`?_!/
MWX%7]CHUO/Y%CJ\WAD>-?&T]M*Q2UU/7)KV:/1?"4$L;I)Y4TH:V9HXI)IO,
MR,#_`(*S_$'XA?MH_M\?"C]@#X?:Q>Q>&/"GB+P]I&JVEA,T-K>>/O$NGKKW
MB3Q7JZE'C>31/!QNVM5="D<LEPH7YU8_TL?LS?LS?"C]E3X9:'\*?A)X>L-'
MTG2;&W&KZO%:00:SXIUH*8]0\1:_>(C/?ZE=7,4LC*[F.$,L<0VYIM-;@?SM
M1>!?^#BO4HAKDGBG5;)W47`T>7Q/\$;*Y1L!O(^QV\,T"\DX1C(/60]![)^R
M_P#M!_\`!:3PK^T;\*OA%^TM\(YM;\`>-O$\.E>(_&OB+P5H,MGHNBPV[ZAJ
M>J6_CGX673V$=]'IL+I#]MAA9G=5,;%<G^DJ-!&I`QRQ/`0#G`Z(@]/<^],>
M$.'!Z.3GIP67RV8;E()\LL,%3GU%(#QG]I;Q?KOP^_9V^.WCSPO=?8?$O@OX
M0?$;Q7X?N_*@F^SZUX?\(ZOJNF2F&ZB>.11>VD.5=64C((K^5C]F3]KO_@MK
M^U[H7B?Q/\`_&&@>,=+\'ZU;:!XBOI=!^#WATV>JWNG6^HQ6L=KKNEQ&XC:S
M^SR>:NX_/M)!+`?U`_ME?\FC?M/?]D`^+W_J!:]7XD?\&VG_`"0S]I?_`++%
MX:_]0#2Z`.1Q_P`'&?\`?\._G^S[_P#(M?HM_P`$[$_X*<?\)7\37_;V_LIO
M#?\`PC^@CX<G3Q\/!)_;?]H79UG[0?!+!PGV0VY_>(BG'&6%?K%10!_/O_P6
ME_;8_:9_9(\4_L]:-^S_`.-H/#,?Q!T_Q<->M+CP_P"&=<.JWEE?Z-:Z6@?7
MM(DCLU_TMU:3>H42EL?+N.S_`,$=/^"CWQ,_:;UOXI?`?]IO6+:]^./@ZX?Q
M!X<U-=&TOPV=;\-1"VL_$&@W.DZ7;0Q1ZWI.J[9&.SS);?5"T@1H60?'G_!Q
MRYC\?_LBR!BIBT_QQ*K``L&CU7PZZ[5)P[9484D!C@$@$FO*_P#@H)\//&7_
M``3Z_;!_9X_;^^%.ER2>"_B3#X6UKQGIMFAAL6\;P^'M.B\>^%KUT6-8;?Q'
MX;CO;Y9"^'O([HS>2%A:0`_L%5@P)&>"0<@@@CL01_G.:_,/_@K7^T/\6?V8
M/V1M;^*7P:\11>&?&D'C?P;H4&J7&FZ7K$4.FZM=W,>H*;#5-.FCEW($`SD\
M\$8(/WW\*?B3X0^,7PZ\&_%/P!J<>L^#?'WA[2O%&@7Z#8[V&K6,-U''<QL=
MT5]&TC1SQN`\4T3QN`R&OR8_X+V?\F!>(?\`LI?P_P#_`$ODH`^PO^"<'QA\
M>_'[]C?X+_%KXGZO#KWCGQ;IFM7FNZQ;Z;::/%>W-IXAU?38Y%T^Q`C@'V>W
MCZ9]3R>/N>OS)_X(\_\`*.S]G'_L!^(__4OUZOTVH`*I:A*T%M)*L;R^6DC[
M(PID8I&SJ(PQYD+*`O(Y(Y'6KM5[I0\10D!7#*V02I#(PYQVIII--[)IO[S.
MJI.G.,7:4DTGV;5N9^4=WY(_@>_:R^./B[]H3]H+XD_$GQE8:AHE]>>(;S1[
M#PEJP<WO@[1=`GFTNR\+W>]ODOH%@;[:J;5^V&;:J@8KYO&<#)).`,G&>/7`
MK]K/^"S'[*G_``J_XP67Q\\,::T'@?XQSK%XBDM4CB@T?XBVUK*UY^ZB4`1:
MCI(DNLXRUY8R.<EC7XJ#=@;MH;`W*O1&P-T9]64Y4^I4U_5G#>-PF.R'+*V`
M@J6%]G9PTYHSCHT[:='^I_C+XG9%G'#OB#Q=E^?U)U\SJXN5;VLK\M6C.[I5
M*;>O)*+NK_,****]L^%$()5E!*AP58C'S*8Y8V7Y@1_JYY1Z_.""&"D?T2?"
M/X6^)/\`@I5_P3O\+>'/$PL_#OQ)_9]\9W'A7X>_$WQ=]J31==T.SMK".YT^
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MQ?7]G7ID#_A*/%6?8$'PAQ2-_P`$1OCJ.6^.O[.N!W'B?Q8VT=S@>#R3^`)K
M\9O[5U3_`*">H_\`@?=__'N:<-5U3!SJ>H]L?Z==]<''26NO^SN*J=ITN(Z<
M)JUG'"4XR5[)VE>ZTOTU/*CQ/X/0G"4?"G%)QE%WCQ!B(O1J]G]5DE=*VST=
MO,_HZ_9+_P""8NJ_LJ?$+6/VC_C#XJ\"_%.P^$7@_P`1^*/"'A?X8OK^OZE/
MXJLM-EG^V30:CX?MA)-#I270M(HR\K7-RDQ58X&63\"_CA\7_$WQ[^*_COXN
M>+Y9'UKQUK=SJK0>8WEZ3IY,D&D:-:-O.+6RTPPV\9_B\HR,`[-7T!^PG^U-
MJG[,/[0WA/QCJVJ7C^`/$CKX-^)MK<W%S<V]QX0U298IKV2%Y&23^S[^>SOC
MO!Q%9S!<;V#=K_P4I_9G@_9[_:"U+5O"ECY/PG^,L,_Q#^&M[9B.;2[>VU"8
M3:_H=@(SB.VT_4+^"1%``6SU6S1054&N/+*6+P'%-:EG.+CCL;BJ*6'K3NHN
M*:E*ERVM&;:4E;1J^NB/<XFQ>3<1>$^68G@C*I<+Y%D685WF^6JL\2Y5<1)1
MP>-J5W&G.I2BKT)J5.-JE6/*FFV?GIT_SU_^M_A24N1Z?YY[_E25]M'F<>>I
M!TJDV^:+W33MKTUM=>1^"J;J.=222DY.+MLW!\KMY:+_`(8*L6US<V4]M=V<
M\]K=VDJ3VES;32V]Q;3QSK<1SV\T#*T<ZS*K*P.Y3RI%0=!GWQ[?YYKV3X`?
M!7Q-^T)\7/!'PD\)YAU3Q?K$=C<7[0BXAT;2H5-[JNO7,989M;72XII'7.6.
MT#DBL,37IX;#UYUG%8?5SYMMM?P.K+\%CLQS'+LMP$)RQ6+K)87V?\66*NO=
MI]FE9ZV/[,OV!/CYKG[27[,OPX^)7BRUNH/%1MY/#OB.^E@%O!K^L>'F;2[O
M6[50NV2&Z:!9Y#%M5)Y9%`50$'X!_M7_`#_\'!'P8`8KN\7_``'4E<9^?P+:
M(2N0<$$Y&<\J.O2OZD?A;\,O"?PA\`^#?AIX)TYM,\+^"=&T[1=&MY)$EG>W
MM+;[.US=7(5?M6H32))<7,FT&2:Y9SC)`_EP_:P7'_!P7\%A@#'C/X"9QCOX
M&L_3W/ZU_)>.J8:MC,95PM)T</6FY0B[7BKZ+339;+0_VTX8PN:X'(,DP>>X
M[^T\VP>$C3Q-9IKVE9*-YQ5E==-4FUJ[:GZA?\%J/V.8_P!IC]EC4/'_`(6T
MD7?Q6^`<.J>.M`DME<:CJW@L0&Y^(/AB(QH6N%ETZWM[V"/*E;C0X]I8221O
M?_X(O?MAM^T[^RQI_@_Q1K"ZA\5O@#)I_@#Q8MQ(#J&J^'%MB/!GBLJ\I9K2
MXTN":S<M\ZW/A^<N?WB`?KU+;Q7=NUO/%'/#+"89X95#1SP3&,2V\BN"LD+Q
MHZNA!#`[3P37\?\`JZW'_!(7_@K&FK-Y^E?LW_'!FO)[I&<Z:GPZ\8ZRT5^)
M3%A4_P"$>\7W,<IW*3##IP*';>$'C/;/9?\`@Y6^]^RE_P!<OB]_Z+\)U^UO
M[0>MW/AW_@FG\2-7M"XN+;]D6YA0Q^8)`NH?#,:;,4:)U:,^1>2?,K!E!+*0
MP!'XE_\`!RA-%<Q_LF75M+'/!/;_`!9ECDAD6:.>&>T\(.L\+`_ZD-W[[A7[
M]>)_A[>?%G]A_4_ACINS^U?'O[,:>%-&\TA8AK>M?#7[%HK3,W"P#59;,OG`
MV@@D=0`?C)_P;>>'[*/X,?M'>,&1)=;UCXG>%]"N+LB/SOL&D>%1=P0D1H`D
M+7FJW<A5<+EOD"\Y_I0C4*@4#"KE5'HJDJHX[``5_*7_`,&X_P`7+'2=?_:*
M_9WUB8Z=KNL)H/Q*T+3+A2ET_P#8`D\*>,+(8_Y;6S7.@[SQR['M7]6JDE02
M`"1R!T#=Q^>:`'51U.PL]5L+S2]1MXKS3M2M;C3]0LYT$D%Y8WD$EO=VLZ$?
M/#)!(ZL.,AB,\U>KR[XV_%+0?@E\(OB/\7?$TBIHOPY\'ZYXMNXV<QF\;1[&
M:YM-+B<`XN+N]6WM8N/]9>+TZT`?RN?\&^$EYX2_:]_:F^'=O=&?2;;X7ZR;
MDJY>&YO/`7Q8TO0M*NH]C!-OD^(=9(.WE;I0FQ00T?\`P4WLKW]A?_@J]\%?
MVLM)MKFV\(?$&]\.?$/6KBS1@+[^PKS2O!7Q=TN.")46741X<ETV[=00)%\3
MJQ#"-P>V_P"#</X=ZS?^.OVEOC=JD9EL8_#OAKX:VFJL-L>HZWKVLOXL\3K&
M2<N5&B:*S-W:?KGK]\_\%ZO@5_PM/]C.'XCV=E]H\1?`OQCIOB]#&B>9#X<\
M301^%?$UOYQ&X0L\VG2.H.&-JA8$JI`!^V]AJEIJFG6>JZ9<0:C8:C90ZEIM
MW:R+);ZC875O'<V=S:S!B&AEBGA9&R00X(X(K\&/^#@+]H>3X>_LS^$O@1HM
MTY\5_'GQ65N;"R8F\;P3X*^R:EJDQ2.0OB?Q%?>'+6%-F9F28+G:0OUE_P`$
M@/CA_P`+Q_8/^$$MS?+>^(OAAI\OPDUO?)++/#<>"/)MM$:XD9MTB/X:?P^>
MN2#@DGD_D+XI;_AX%_P7!TC0V:/5_A7^S%<V$,D3L;O3O[.^#]U/JVK;UF.R
M>"]^(^IB,,!^_1"3N6-10!^Y_P"QA\";C]D[]AKP#\-+FQ73_&'ASX::MXK\
M9QQ*/.C\?:_IEYXGU^*6=%4SW5MJ%Z;3S,DD6(P<;:_!+_@W8TN#Q+\?OVI_
MB+J6VY\0)X%T""*>X_>213>,?&6I:QJL\:OEEWW&DVJL0WW5`.22:_K&U>P7
M5=,U'2IV$<6IV-UITIR"-M_:W%M,$X^]F;OUP*_D._X(K^(F_9X_X*(_M`_L
MZ>+V32KOQ5I_B_X?:?;71:,3:_\`#SQ5J6IZ9#"Z<//-X=T_7I,GC"#D4`?V
M%4444`1.`6!RP*QN00./O(01QRP*+[>H.:_D$_8"LX/AU_P7(^-W@_P]&MGH
MLOC/]HCP\MI;K^Z33/M5]JL-HP3`6!+RUMG`P"'C/-?UTZ[J]AH&DZEK>JW4
M5CI>CV-SJFI7<SA4MM/L();N\F?/\`@@?Z_A7\C7_!'E;G]HG_@J'^T%^T=8
MQ[_#MI:?%/QRMYO!1KCXA^++G2O#MOD\L)-(O9)^/[GH#33M?S`T_P!@*(>/
M_P#@NI^TKXCUUEN;OPSX\_:CETMI")BA\/\`BC5/`-@5,@8+)'I%T@B*X*K"
M,?+Q7]<X0*<C@D`'@#..F<#MS_WT:_CE\"^(HOV.?^"\GC1_%[+I7AOXF?%G
MQK:37K';"FG?'G3]0UKP_J#JG#0CQ%J^EKW^>0$YQ7]B\;%B<DG:&!/\+-O9
M#@=L&,_]]T2=[65K`2TW+`G(XSQ@<G_Q[^G:G5_-S_P6S_:[_:0_9S^/'[-W
MA;X)?%?Q)\/]$\8^#]6O_$>F:&UMY6K7<'C&SL(KB>.:)BTBV<CQC!`VMCK2
M`_;7]L=2_P"R3^TX@X+?`/XMKR">#X$UT-T/'RYYZ#J00,'^/G_@EM_P5'\'
M?L"?#WXI>$?$GPB\6_$=_B'XUTGQ5:W_`(;UW2],M]+2P\-6>DO87)U"R87$
MK"..161E.`_R8'R_V"?ME?\`)H_[3QY!'P!^+I!!(((\!Z\0>/<"OPI_X-R_
M"?A;Q!\$_P!I*YU[PUX?UJX@^+OAJW@GU;1M.U&6"`^!-.F,$,EY;.88?-ED
M;:I"[G)QF@#9_P"(D/X3_P#1KOQ0_P#"S\,?_(%?K'^P+^W+H'[>GPL\6?%+
MPY\/=>^'%EX5^(][\/)-(\1ZI9ZK=W\UGX7\,>)3JL%S8VL4:0,OB:.$)AR'
MLG^?+87ZX_X5K\.O^A!\%?\`A*Z%_P#(%;ND>'M`\/PRVV@Z'I&B6\]P;N>W
MT?3;/3()KMHHX&N9H;*%%EN###$F]@6VQ*N<*``#^6+_`(./!GQY^R/GMIWC
M@_\`?.K>'2/PR*_<#]JK]E[2_P!K_P#8EO?@U=_8X?$&J_#KPWK7@75K]5,&
MB^.M$T&UO?#]_+)C,%L]RIM[A@1^XO'!RN5/X@?\''?_`"/O[(__`&#?'7_I
MU\/5_3Y\/_\`DGW@+IC_`(0[PQNR2!M&AV);..VT&@#^=W_@@M^U+K>GGXD_
ML'_%A+[0/'?PRU3Q-X@\!:%K\K)J=G8:=JXT_P"(7@*=)2,:IHVO2)<A0-T\
M>I7\J`QV35]7?\%Z&W_\$_\`7W_O?$GX>D9!4X-])U5AE&]0>0>.U?F]_P`%
M=?A/XT_8@_;-^$'_``4+^#-I);Z9XJ\5:7<^*H;2,_8(OB+X?TV[MM2TK5D@
MVYL?$OA*:_WDY\R33-0=_FD)K[5_X+"?%;PC\<_^"5N@_%GP)?)?^%/B!XG^
M%'B#1Y$<R30KJ,[R-IMQ(>MY;W`GMY_^FMNPH`^PO^"//_*.S]G'_L!^(_\`
MU+]>K]-J_,G_`((\_P#*.S]G'_L!^(__`%+]>K]-J`"HI0"`",]>GTQW^OZ5
M+3'Z#Z_Y_E1IUU#39JZ>Z[KL?-O[57P#T/\`:6^!?CWX0:VL5O/XBTB2?PUJ
MLJ[FT/Q9I6+KPSKD9520(=56U\P`;FA,BC[QK^$3QMX.U_P!XO\`%'@CQ/I\
MFF>(/">O:GX?U?3Y.MK?:;>RVCP(`3^Z(C5H0,EHF1ERO-?Z)#*'QNQP-H)S
MGDY8$@?=^5,?0U\-_%O_`()V?LB_&SQ]KGQ)^)'POCUKQAXB%J-8U.U\1^*M
M&6\-K:-912O9Z1JL,/VO[.Y!G$:R$JI8D@&OON#.,J?#GUNCCE.M@\1:48QU
ME&HK+2[LHN-[KO;4_F/Q]\#\;XFSR7,N'ZF&P>>9?>A5J8BHZ4*N&:;BI.%*
MI*52G-15/9<DIWNTC^'3!]#^1H(?*@8!9U4!@3DE@,J`"69?O``$DH,`FO[2
M!_P27_8*8@#X,S$^G_"<>.^?_*\/YTD__!)']@YDPOP5E`8,CX\=>/AO1E*X
MW#Q(,,21@C.,9'(%?=Q\5<BDY6PM=::7Y-^E_>6GH?S<_H@^)#IU)+.,JC)<
MO*E5Q%2[;7-=K#QM:.RMOU>Q^2G_``2_^&7A3]GOX/?%C_@H-\8+-ETWPQH6
MMZ#\*;&^#-)?2V\8M-7U#39K@!%U34]5NH=)MVW#Y1<[L)&[+^,OQ8^)7B7X
MQ_$?QE\4O&-T]UXE\::_>:YJ+\XMXY;EY;33+3CY(8+,6T"`XPMN!7[_`/\`
MP6@\$^)OA/\``'X`_#'X8Z!8>&?V;=%U>;2-9L=)\R00^(M/T^8^$++61<,?
M]!&G0:O.EPSL9K\.;@^8\!?^<!G\QGE*LGFL\K*ZLI5YG\R3*.`4.]V.TX*\
M*0,8KV>$9+-HYGQ55?/B,P;PT$W=TL.FDJ<>SO=OU/B_&VE5X,_L/PKP].2R
M_A6A3K8FI9J.,QF/LJ]9.T.=1IOV-)N'-"/-U=QE'K[_`.>?6BBOM;:)=OT/
MP=QNK)V6GX.XC#*X(WK\Q*!C&6_=30NCR#D*T=RVW'0H2<9&?W8^!=VG_!07
M]@?Q?^SEK,Z7W[0'[,EF/$OPE>]9)+[Q3X=LK:=]*MK&=V#?:1%]JTB=2%78
M]B2WESRE/PHK[]_X)CW7Q-M?VT/@]_PK&*.6ZO=2N+3Q?#<22PV4GP_\ASXN
M^WRQJ2D,>FB.[B."IN["SB!S(PKYOBW">VRJOF-.:H8K*N6M"=[-<LE%I/\`
MO)M/R;/TWPHS7ZGQ13R7$X:6/R7B]QR[%X:$>9S6*G&G1JPCJE+#UW3KJ332
M=.[32/@65'@DEAG1K>:!VBG@G!AGAF2:2W>*:&3#1S+/')&ZD!D="K`$$5'D
M>H_,?XU_9U\0O^"3/['7Q0\>>*?B'XD\)^*[37/&NK7.MZR/#_CGQ#HFGRZE
MJ$K75\\&F6EUY-I%)?&:Y=44?OYV(.TA:Y'_`(<L?L.?]"]\2.W_`#5#Q1^/
M_+:OFEXJ9(U%XJE5^L.,.;EM:ZBD][Z_UL?K.*^B)XET\9C(Y=B\NJX"-6<*
M+KXB=*HX0ERJ4HQI5$W.W.VG%7;]U'\>N5QDLH&X9RZ`*"K,6;)^50%.6.%7
M')%?U`?\$6/V2V\&>`M;_::\8V*)XE^(T,^@?#V"X1"='\"V4I74-71G7,5_
MJNIQ2KN4_)9:9"`1]HE6OHC_`(<L_L/!E)\.?$*5`\;O#<_$SQ3+`ZHQ,D4B
M"Z4212*55U/4(`".2?U&\,^&-(\(^'M&\*^'[*'3="\/Z19Z-I%G#GR;:QLH
M([>W@4,<E5AB098EFQECDDGY3C#Q`P><Y7++\KA.DJSO.4DN:RZ1MIJ[)WZ'
M[#X'?1PS[@KBQ\2\9RPN*65T_:8&G0G[6$,4[)U.:48MM+9J,==EH=(NX`9S
MCY>?H1SCL/\`/2OY*/VLI8Q_P<%_!8^9$=WC'X#%0LB,[;/`M@Q41J2V_:R$
M+C+!OE!K^MEEW(4."&7:P.<%3PPX[[<XKX/\=_\`!.C]GOXC?M5>&?VQO$A\
M>CXQ>%-2\,:KI0TSQA+8^$S=>$K"#3])%[H`T]A>Q""VA#@R+OP>1W_+#^T6
MKV=[6/NZ`YC'7C`.0000HR,$5^37_!8S]D7_`(:D_9-\0:IH.D#4/B7\$I+_
M`.)7@B2*)7O[RQL[&)?&/AJV549IH;SP_!+-Y8R[W6AVJHK-M4_K/&GEJ%XX
MSC:-J@=@%R<#'O[]ZBDB:0D,0$W@C!.2G[LNKJ00X8JZG/\`"Y%`S_/;_:._
M::3]H;]B/]E/PMXAU62?XA_LY^(/'_PRU2"ZFWSW7@#5=#\/7?PWU**:0Y>*
M"#2=7TB5CA6CT&S(XVLW][/P:^;X/?"@+N)/PU\!<HVT[3X8TO+HW0X$J'^7
M(Q7Y;^+?^"#_`.P5XN\6^)O%\ND?%/0KGQ3KVH^(KC1O#'Q!71O#FDWFI7MQ
M?3VN@Z5#H#?V;IBRW=PL4`D9(8F\N/:I-?K[X7\.V'A+P[H/A?2C,=+\.:)I
M.@:=]IE,UT;'1M/M]-M#=3G_`(^+C[/;1[GP,D=*`/Y(O^"D_P"S7\:O^">_
M[7^G?\%`?V>M/DA\`>)?%TGC'Q!<:1;23:1X/\:ZVS0^-M!\56T2@V?A#73J
M.IRK<R/Y#RW\@G,<EI`)?VC_`&3_`/@KS^Q_^TEX:TB/7OB1X7^"GQ-^Q1+K
MWPZ^)>KVGA[RM0\I!-)X7\1ZE+!8^(M%:<R?92DBW+Q*K/;ID%OU`UW0-%\3
MZ5J&A>(=*TW6]$U:U>RU/2=6LK?4-/O[63.ZWN[2[C>.>(Y/#(W)R,$`U^-7
MQN_X(,_L0?%G5+O7?"T'Q!^".I7DK7%Q9?#7Q!8R^%;NXDF,TLMQX:\7:1J7
MV)BS/C^S+G30"^0N<[@#]$?'W[9O[)?PVT6XUKQO^T=\'-!T^&(2_/X_\/7E
M_=#&Y8M/TK3+Z:[U*=@,"*VAEE;)"KFOYG_V^O\`@H9X^_X*3>*="_8Q_8I\
M(>)=<\#Z]X@TY?$.MWEC<:5?^/;RUN'>Q&KVA`D\(?#>T+QW=Q)J!BNKA+%)
M#&N%1ON+PE_P;B?LFZ1?K=>*_B_\=O%EFCASI%E=^`?"UG=`-Q#?7$'@F[N&
MAV%@?L\MM)TVR+7Z_P#[._['?[.?[*>B'1?@3\+O#W@KS8UBOM:1+G5/%.JQ
M@1[DU+Q3J\\]]/&\D43O'YPA9HQB)0```<;^P5^R1H'[%W[-_@OX-:;<PZOX
MA@2;Q!\0/$D$9CA\0^.=;2";7;^V5P&.GHT-O:VI8!WMM.A=P&)`^@/C!\,]
M&^,OPN^(?PG\3QLWA[XC>$?$/@S4W15D>UM-?TF>P&HQ1LZ@W-M<RQS1#.-\
M`R.X])BC\M`N0<8Y`"CH!@*.%4`8`[``5)0!_%5_P3:_:XU?_@GS:_M_?!KX
MH3VVE^*/!'@OQEKGA+39Y5:WG^-/PMUFX\#3:7813G-Q:7=WKEC>1*FY9;30
MYC'O(45^FO\`P;[?L_7N@_"+XL?M3>,8I+KQA\=?%]WH6@ZC<_O;@>#?!VI7
M5QJFH+=;OFDU;QIJ.HRS`95AX=MF4D+D_7OQR_X(Q_L9?M!_%SQA\:O'=A\2
M;/QEXZU.WU;Q"GA7QR-!T6XO[6&*);Z/3HM#<K<RO$\D^)`KR7<I.<BOT0^"
MWP?\&_`3X7>!OA!\/;.:P\&?#WP_;>&]`MKNY:^OFLK5F<7-]?.B&YO9IY+B
M:=RHWS73D8&!0!Z<Z$DL"V?DP!@[=A8_*#W.X@^U?RP_\%C_`-BKXJ?!SXVZ
M/_P46_9CCU"UN=*U#P_K/Q+BT&TFN=2\$^+O#)C_`+)^(,-K`A$_@N[TV*.W
MUBW;,4=S"UPY6.[F9/ZHZHWEA!J$4]K>V]K=V=U!):W5K=PK=07-K.A2>WEM
MY@8VB88W*RNL@&&7@4`?C9^Q/_P6=_9J_:#\*Z+I7QI\8^&O@3\9+>VBT[7M
M%\67)T3P1K>KP;EN[[PGXLU*3[+;13/ADTR_G@O[<95EN,>8/T4\4_M>?LJ^
M#]%FU_Q/^T?\$-%T>&)IVOKSXG>#A&ZJC,!;I%K!DNI3CY(X5>23&$4FO@W]
MH/\`X(@_L,?'O4[[Q%:>%_%'P7\3ZC,]U>:I\']:L]'TZ\N7Q_Q]^%/$.DZE
MI(AR`2;6RM)R1GSP,@_+?AS_`(-P?V7--U*.YUWXZ?'W6=/1MSZ?IK?#?0)K
MA>-T-QJ/_"#73-"P^]Y<<3\`JZ%10!\W?\%(?^"KH_:@L'_8X_89T_Q-XXD^
M)URGA/Q9X^TO2M0TZX\6:=>L%D\,>!=+U"%;N/2IS(/[1U.XB@5;9R,)`%FF
M_7W_`();_L,K^Q+^SQ#H'B2VLY?B_P#$F^L_&?Q7U.T,<@MM1-L%T?P;;7:C
M_2--TBUN9H5/S*UQ>7[QLRRJS^X?LS_L$_LM_LBP,_P/^&&E:'KTUHMI=^--
M:EN_$GC:]3"K()O$>K32306\@7]Y!;"WB<D_*`<5]C*"%`8@MCYB`0">Y`).
MT9Z#)P.,F@#\`O\`@M)_P3E\3_M&:!H_[2?P-TBYO/C/\,+%++Q#H&G7$=IJ
M7C+P38W+ZA8ZAH<D461XLT6^5I[>/.+BU.T'SHU5O!_^"?\`_P`%R/!VF^%=
M`^#7[:S:OX5\5^%+=/#EA\8FT?4;[2]4MK!8[:RB\?Z);PR7^B>(8TA=)9XH
MIEG\KS)(XSES_3JP)'&,Y!&>!P0>>#Q_GCK7Y[_M*_\`!+[]C?\`:JU"\\0_
M$KX76FE>-]1$IOOB!\/+N?P1XMNKB08%U?7%@)+76Y@"W_(2M+WD@@C;M(!Z
M]X?_`&XOV./$6FQ:KI/[4'P*GL9HA.LMQ\3_``K8/$I17*7-OJFIPRV4P!R8
MI420!@2@W"OYA/\`@N?\;/@_\;/VE/V8;GX/_$_P)\3[?PWX1U#3M=G\">*-
M(\4PZ7?7_CBPFL[6ZET:[F59I(E+``G`&6VY&?T&NO\`@V^_90DU'SK+XY?M
M&V6E;\IIK7_PIN;N.,G+1KJO_"KD++Z?N!R22237T?\`"G_@A1^P3\,;RSU3
M4/#OQ%^*FJZ;<0WEA<_$KQT]Q:6]U!*)TD.A^#])T?3KD><J'%Q:7&-@Y)H`
M^_OVRO\`DT?]I[K_`,D`^+HX!/7P%KPR<#A?4G@#DD`$U_.W_P`$"?VE/V>_
M@7\&?V@--^,WQL^%WPMO]?\`BOH.H:)9^//&_A[PQ/JUC:^"M.LKB[T]-6OX
MOM4"W4;H63/*Y'RD$_U#?$/P/HGQ.\`^-?AQXE^U_P#".^/?"NO^#M=^P7!M
M+XZ/XDTNZTC4A:705OL]R;.\FV/@[6(.#C%?CK_Q#_?L"[F)3XVYW,RO_P`+
M1+3'>D,;*\TOAYF9-EM!A<X!!XZ&@#[W_P"'A7["?_1X/[-__AXO`O\`\NZ[
MOX=?M=?LM_%[Q+#X.^%?[0GP>^(WBNXM;N]@\.>"?B!X:\3:S+:V,2S7DZ:?
MH^HS2F..)U9CMX!K\SO^(?\`_8&]/CA_X=(?_,Y7T!^S'_P25_91_9*^*]A\
M9/A,GQ*'C'3=,UK1;9O$_CEM<TS^SO$%E!::AY^GOI$8EN0(<QL&0+GD'N`?
MD%_P<>R1IX^_9(#R1QD:9XZ8^9(D?`U7P_TWL-Q^4],_J,_U"?#KCP!X$4D9
M'@SPUQGDXT73\D>HY'(XYKY(_:\_X)Y_`#]MO5?`6L?&M?&QO/AM!J-OX9'@
M_P`5R>'+<+JEQ9W5T=0MUL)A=`RV4("[A\GREJ^UM'TFWT33=-TFS:7[%I.F
MV6E62RR%W^RV,$=M`9F(_>SB&&(%^-QR=HS0!\W_`+9?[-WA[]K']G?XC?`_
MQ!'!')XJT82^&=6E3<_A_P`::7<PWOA/6T9?F2*#5XX3,0"?(:4`$G!_BFL_
MCSXF\+?L0?M+?L"?%\76D^)?AC\3?#WCKX<V5Y(3<6&HZ3XPAT3XA>"+%)#E
M;%)IK?5;)8=^]9+YE+&2$/\`W],@8Y8`@!<<D'(8-SCH`RH1]#7Y7_M$?\$=
MOV.?VF?BYXE^-7Q`TOX@Z7XS\7MILGB`>"O&J^'-'O[G3;!+'[;)IQT2?_3K
MA$C^TS!U:3R48;2""`;G_!'@@_\`!.S]G':0P&A^)/F0AT/_`!6&O+\LBDJW
M(/0GU''-?IO7BO[/WP'\$_LU?";PA\%_ANVM?\(7X)M[NTT8>(M5DUS66M[J
M]O+Y_MNJ211FY?[1=L?N#&,9/6O:J`"D(!&#2T4`,\L=B?YTH7'\3?@<4ZBB
MR>ZN`PID$;FY]3G],5&+=/XOG]`P']!4]%--I66@K>\I7:<=K-K\$['@7[27
MP.\-_M"_!OQU\)/$\2-I_BK1)(;"Z,<+R:1K]FYN]`UFV$T+JMQ;:O'8RC*.
MKB`HZLK%3_!S\1O`/B7X4>.?%?PX\8VK67BGP9KEYX>U>W=9$DDO;)W/VI(Y
MB7-M<VD;3P.7;*RJ2S<Y_P!#R5E!(.00I.0,]B>GKUQ]*_FV_P""VG[)X27P
M_P#M7^"M/_=7+V?@_P"+,$$2!#(L1M/!WBN=E4&%0)]2L[LG+.\E@3]PU^D^
M&_$$L%F+RK&5''!XV:<+O13T2^;2[[I:,_D;Z5_AM+B#AJGQIE%%5,ZX<C'Z
MQ"W\7`1E>I6EK=RPU^:%OYG>]C^=>E&._P#G\/6DZ4H]/Q/KQG_&OWMSB[6F
MM;=5W/\`.-4*L[1A"7,[<NCUDM8QVVD[1?DV-)"JS,0%!!)`)*(J2O(S^N=J
M!<8Y)SGC']6'_!&7]E(?"[X47_[0/BW3PGCCXM0"W\.BYC=;GP_X`MIE$2)'
M*=UO<:CJ%B;J8YPUM8VB(B'S6E_`W]AO]F:__:J_:(\&_#@6]P?"MI<1^)_B
M)?QF:-+/P5H=U;3W]JL\8_=75_+(EC#)UAFOHWYW5_<WH^DZ9H6DZ7H^D6<5
MCI>CV=IINGV5M&(8+6SM(([>TABB4#8BV\4:A<?*$V]*_*/$OB*-*$,AP\N6
M5:TJC3W@EI%^LK/Y?(_LWZ)/AI4S#-,3Q_FM!.AEDY4\"I)_[TTO;))VTHKF
MA%V=N:^ZNME5`()/)(&!@C<!P1],U-M'TYST'X=JA5<E,'HQ8$Y&0PS^?2IZ
M_$91BWT;TOH?Z#07N1;TD[MJ[LG?7\1NT9ZG&,8X`Y.>P]12%`<\D9].@P<\
M?Y[T^BA:;:%62^3O\P'``]****!A1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`PH"P;.#_GO6#K^@:/XCL+G1M>T;3-=TJ]0QWFF:U96>I:7=1<8C
MNK&^@EBN%_V7C85O,&)X.!]2/Y4@3GGI[?\`ZJ:;333U1G4I0K1<*L5.#Z/8
M\;/[/_P3R?\`BS?PGZG_`)IQX,/Z_P!@\TO_``S_`/!$`E_@U\*3TV[?AUX.
M0@\YY71!D8^M>P^4/1?UI1'CT'TST].:TCB\1=+V]3Y[=.VO],X/[%RA:K+<
M.WY4*4?Q2NO7<X3PU\-_`/@J>YN?!_@/PAX5FO(HHKZ;PWX=T309[N&%W>*&
MY?2K*%KN(.[$)(Q0$[@`2<]Y$"$&>N6/)!QECCD`<8P![<4%.P`(/J3G]*>!
M@`?R_P#KUG*52<W.<W)_UW;.RC0I4(\E'#PH0[15OOM_6@M%%%(W"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
B***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
